Business Wire

VA-REGULA

14.5.2024 09:01:37 CEST | Business Wire | Press release

Share
MWC Events Powered by Regula for Identity Verification for the Fourth Straight Year

MWC attracts tens of thousands of visitors, including representatives of mobile operators, device manufacturers, technology providers, vendors, and content owners. To ensure everyone's safety, the GSMA has traditionally conducted thorough registration and ID validation processes for each attendee.

For many years, the ID validation process was done on-site at the venue, which caused queues and long wait times. With the advent of the pandemic in 2020, and attendance now regularly exceeding 100,000, the GSMA had to find a contactless solution to remove the need to have attendees wait in large numbers to collect badges and have their ID validated. To address these issues and improve the efficiency of the registration process, the GSMA decided to make it totally remote and digital, so that all attendees could swiftly get access to the venue through the entry gates. Any solution would also need to enable quick and efficient international document recognition, because attendees come from all over the world.

To achieve their goal, the GSMA ran an extensive competitive tender process to find the best technology solution. Ultimately, they chose a complete, single-vendor solution by Regula which includes Regula Document Reader SDK and Regula Face SDK. Natively integrated, these solutions facilitate a smooth customer journey and rapid onboarding through seamless and secure identity verification, eliminating the possibility of fraud.

Having successfully piloted Regula products during MWC Barcelona 2021, the GSMA fully transitioned to digital visitor registration and ID validation. After several years of collaboration, this long-term partnership led to a significant enhancement of the visitor registration process, enabling a fast and convenient user experience. Now, Regula Document Reader SDK and Regula Face SDK are easily integrated into the MWC’s existing registration platform for full-fledged production use.

Now, as part of the registration process, an MWC visitor simply uploads their ID on the official website. The identity document is automatically scanned by Regula Document Reader SDK. The solution instantly recognizes the document type, reads its data, and verifies its authenticity with multiple cross-checks. Not only does it streamline the verification process (checks are completed in seconds), but it also minimizes the chance of missing compromised IDs.

Further, an MWC attendee has the opportunity to provide their selfie, which is rapidly captured by Regula Face SDK for user verification.

With the industry’s largest and most comprehensive identity document template database, which contains over 13,600 templates from 249 countries and territories, Regula supports the verification of nearly any identity document from any part of the world. Taking into account MWC attendees’ geographical spread, this ability significantly facilitates the registration process.

With Regula’s complete IDV solution, the GSMA managed to create a custom, smooth, and seamless registration experience for all MWC attendees. During the Barcelona event in 2024, Regula solutions helped to efficiently validate more than 100,000 visitors – all of them registered online beforehand, so there was no need to queue at the venue.

"Our collaboration with GSMA for MWC highlights the power of digital transformation in handling large-scale international events. By integrating our advanced ID verification technologies, not only did we enhance the security and efficiency of the registration process, but also ensured a seamless experience for attendees," says Ihar Kliashchou, Chief Technology Officer at Regula.

“The digital identity verification process has revolutionized the visitor experience, allowing more than 100,000 individuals to register and access the world’s leading connectivity event swiftly, safely, and without interruption," states Xavi Casals, Director of Technology, Innovation & Customer Experience at GSMA.

For more details on the business case, please visit the Regula website.

About GSMA

The GSMA is a global organisation unifying the mobile ecosystem to discover, develop and deliver innovation foundational to positive business environments and societal change. Our vision is to unlock the full power of connectivity so that people, industry and society thrive. Representing mobile operators and organisations across the mobile ecosystem and adjacent industries, the GSMA delivers for its members across three broad pillars: Connectivity for Good, Industry Solutions and Events.

Find out more at gsma.com.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514134027/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye